Nippon Telegraph and Telephone Corporation

Tokyo Institute of Technology

Celgene Corporation

Fujimoto Pharmaceutical Corporation

Kentaro Hotta

Hideki Ando

Hiroshi Handa

Takumi Itoh

Yuki Urabe

Shiro Ogasawara

Takumi Ito

A document acquisition unit () collects documents, a feature amount calculation unit () calculates feature amounts of words included in the collected documents, a relevance calculation unit () calculates relevances between the documents and words included in operation logs in a window operated by a user, using the calculated feature amounts of the words included in the documents, and a presentation unit () presents, to the user, a predetermined number of the documents in an order of descending relevance, as related documents. In this manner, it is possible to present documents related to a user's operation to the user.

Presentation device, presentation method and presentation program

With an aim to provide a novel factor inducing proliferation of neural stem cells and differentiation of these cells into nerve cells, a pharmaceutical composition comprising 1) CRBN, 2) a nucleic acid encoding CRBN, or 3) a stem cell or a neural progenitor cell in which CRBN is expressed, a method including administering the pharmaceutical composition to a non-human animal and inducing proliferation of neural stem cells or neural progenitor cells of the non-human animal and differentiation of these cells into nerve cells, and a method for screening for a therapeutic drug for a disease of cerebral cortex or a surgical injury of cerebral cortex, using CRBN, are provided.

Pharmaceutical composition containing core factor involved in proliferation and differentiation of central nervous cell

With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.

Screening method utilizing thalidomide-targeting factor

Growing community of inventors

Tokyo, Japan

Kentaro Hotta